MLZ Stock Overview
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
MediPharm Labs Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.046 |
52 Week High | CA$0.06 |
52 Week Low | CA$0.03 |
Beta | 1.04 |
1 Month Change | 16.46% |
3 Month Change | 15.29% |
1 Year Change | 0% |
3 Year Change | -85.16% |
5 Year Change | -97.88% |
Change since IPO | -97.40% |
Recent News & Updates
Recent updates
Shareholder Returns
MLZ | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 8.7% | 3.0% | 1.3% |
1Y | 0% | -25.6% | 6.4% |
Return vs Industry: MLZ exceeded the German Pharmaceuticals industry which returned -25.6% over the past year.
Return vs Market: MLZ underperformed the German Market which returned 6.4% over the past year.
Price Volatility
MLZ volatility | |
---|---|
MLZ Average Weekly Movement | 16.6% |
Pharmaceuticals Industry Average Movement | 6.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MLZ has not had significant price volatility in the past 3 months.
Volatility Over Time: MLZ's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 130 | David Pidduck | https://www.medipharmlabs.com |
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada and internationally. The company formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. It also provides GMP flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll products.
MediPharm Labs Corp. Fundamentals Summary
MLZ fundamental statistics | |
---|---|
Market cap | €23.34m |
Earnings (TTM) | -€10.69m |
Revenue (TTM) | €20.08m |
1.2x
P/S Ratio-2.2x
P/E RatioIs MLZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MLZ income statement (TTM) | |
---|---|
Revenue | CA$29.55m |
Cost of Revenue | CA$25.96m |
Gross Profit | CA$3.58m |
Other Expenses | CA$19.31m |
Earnings | -CA$15.73m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 27, 2024
Earnings per share (EPS) | -0.039 |
Gross Margin | 12.13% |
Net Profit Margin | -53.23% |
Debt/Equity Ratio | 4.5% |
How did MLZ perform over the long term?
See historical performance and comparison